Karus Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Karus Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013978
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:17
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Karus Therapeutics Ltd (Karus) is a designer and developer of molecule cancer therapies. The company provides treatment of a diverse range of solid and hematological cancers and small molecule drug. It develops two clinic-tracked programs potent and selective inhibitors of PI3K and HDAC for the treatment of inflammatory disease. Karus develops and markets medicines based on the potent and isoform-selective inhibition of two enzyme families such as histone deacetylase and PI3 kinase. The company’s development programs offer medical needs in the fields of chronic inflammation, retaining drug design, immunotherapeutic modes, haematological malignancies and solid tumours. Its HDAC6 inhibitors are anti-tumour agents for the treatment of multiple myeloma. Karus is headquartered in Oxford, the UK.

Karus Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Partnerships 12
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd – Key Competitors 14
Karus Therapeutics Ltd – Key Employees 15
Karus Therapeutics Ltd – Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
About GlobalData 17
Contact Us 17
Disclaimer 17

List of Tables
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Karus Therapeutics Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Karus Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Karus Therapeutics Raises US$7 Million In First Tranche Of Series B Financing 10
Karus Therapeutics Enters into Agreement with University of Texas MD Anderson Cancer Center 12
Babraham Institute And Karus Therapeutics To Explore PI3 Kinase Inhibitors In Treatment of Inflammatory Diseases 13
Karus Therapeutics Ltd, Key Competitors 14
Karus Therapeutics Ltd, Key Employees 15

★海外企業調査レポート[Karus Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Resolute Forest Products Inc (RFP):企業の財務・戦略的SWOT分析
    Resolute Forest Products Inc (RFP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • SQI Diagnostics Inc (SQD):医療機器:M&Aディール及び事業提携情報
    Summary SQI Diagnostics Inc (SQI Diagnostics) is a diagnostic company that provides in vitro diagnostic and pharmaceutical research products. The company provides products such as sqidworks, sqidlite and sqid-X. Its sqidworks system is used in labs. SQI Diagnostic’s sqidlite is a practical benchtop …
  • Keio Corporation:企業の戦略・SWOT・財務分析
    Keio Corporation - Strategy, SWOT and Corporate Finance Report Summary Keio Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Inflection Biosciences Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Inflection Biosciences Ltd (Inflection Biosciences) is a drug development company focused on discovery and development of small molecule therapeutics for the treatment of cancer. The company’s pipeline products include dual mechanism kinase inhibitors and pim kinase inhibitors including IBL- …
  • Puracap Pharmaceutical LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Puracap Pharmaceutical LLC (PuraCap) is a drug development company that offers prescription generics and OTC products. The company provides over the counter soft gels and oral solid dosage healthcare products for upper respiratory, pain relief, cough and cold, sleep aid, gastrointestinal, an …
  • Pan Malaysia Holdings Berhad:企業の戦略・SWOT・財務分析
    Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report Summary Pan Malaysia Holdings Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • F.N.B. Corporation:企業のM&A・事業提携・投資動向
    F.N.B. Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's F.N.B. Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Hanmi Pharmaceuticals Co Ltd (128940):企業の財務・戦略的SWOT分析
    Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Zecotek Photonics Inc (ZMS):医療機器:M&Aディール及び事業提携情報
    Summary Zecotek Photonics Inc. (Zecotek) is a photonics technology company that focuses on developing advanced materials and integrated optoelectronic devices for optical precision surgery, high resolution medical imaging and biopharmaceutical research. It develops and sells scintillation crystals, …
  • Enel SpA (ENEL):電力:M&Aディール及び事業提携情報
    Summary Enel SpA (Enel) is an integrated electricity and gas company that produces, distributes and trades electricity and natural gas. The group generates electricity using diverse sources of energy such as nuclear, renewables, oil and gas turbine, coal and gas combined cycle. It also focuses on di …
  • Flexion Therapeutics Inc (FLXN)-製薬・医療分野:企業M&A・提携分析
    Summary Flexion Therapeutics Inc (Flexion) is a pharmaceutical company that develops and commercializes pain therapies. The company's products comprise FX006, FX007, and FX005. Its FX005 is a p38 mitogen-activated protein, kinase inhibitor that contains both analgesic and anti-inflammatory propertie …
  • Innovative Solutions and Support, Inc.:企業の戦略・SWOT・財務分析
    Innovative Solutions and Support, Inc. - Strategy, SWOT and Corporate Finance Report Summary Innovative Solutions and Support, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Gridsum Holding, Inc. (GSUM):企業の財務・戦略的SWOT分析
    Gridsum Holding, Inc. (GSUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Airest S.p.A.:企業の戦略・SWOT・財務情報
    Airest S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Airest S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Riyad Bank:企業の戦略・SWOT・財務情報
    Riyad Bank - Strategy, SWOT and Corporate Finance Report Summary Riyad Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • African Development Bank Group-エネルギー分野:企業M&A・提携分析
    Summary African Development Bank Group (AfDB) is a development finance institution. It promotes social and economic development by providing loans, grants, guarantees, equity investments and technical assistance in its regional member countries. The constituent institutions of the bank include The A …
  • Alfa Wassermann SpA-製薬・医療分野:企業M&A・提携分析
    Summary Alfa Wassermann SpA (Alfa Wassermann), a subsidiary of AlfaSigma SpA is a pharmaceutical company which produces and distributes drugs for human health. The company provides new discoveries in medicine, biology and genomics. Alfa Wassermann finds solutions for paradox treatment. The company o …
  • Lietuvos energijos gamyba, AB (LNR1L)-エネルギー分野:企業M&A・提携分析
    Summary Lietuvos energijos gamyba, AB (Lietuvos), a subsidiary of Lietuvos Energija UAB, is a state-controlled electric utility that generates, imports and exports, and supplies electricity and thermal energy. It generates electricity from hydro, thermal and renewable energy sources. The company tra …
  • Greencore Group Plc:企業のM&A・事業提携・投資動向
    Greencore Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Greencore Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • CME Group Inc.:戦略・SWOT・企業財務分析
    CME Group Inc. - Strategy, SWOT and Corporate Finance Report Summary CME Group Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆